Edition:
United Kingdom

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

35.02USD
19 Oct 2018
Change (% chg)

$-0.15 (-0.43%)
Prev Close
$35.17
Open
$35.11
Day's High
$35.28
Day's Low
$34.47
Volume
126,181
Avg. Vol
132,459
52-wk High
$48.31
52-wk Low
$19.00

Chart for

About

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $1,163.30
Shares Outstanding(Mil.): 46.93
Dividend: --
Yield (%): --

Financials

  XNCR.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -0.87 -- --
ROI: -14.67 0.21 14.27
ROE: -15.16 1.17 15.99

BRIEF-Xencor Reports Q1 Loss Per Share $0.62

* Q1 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S

07 May 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $44.50 +0.50
Novartis AG (NOVN.S) CHF87.04 +1.16
Roche Holding Ltd. (ROG.S) CHF244.95 +6.40
Roche Holding Ltd. (RO.S) CHF245.20 +5.80
AstraZeneca plc (AZN.L) 5,934.00 +56.00
GlaxoSmithKline plc (GSK.L) 1,557.60 +47.00
AbbVie Inc (ABBV.N) $87.97 -1.93
Bristol-Myers Squibb Co (BMY.N) $54.30 -1.68
Bristol-Myers Squibb Co (BMYMP.PK) $1,050.20 --
Amgen, Inc. (AMGN.OQ) $201.80 -0.92

Earnings vs. Estimates